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Abstract
Background: Hyaluronan (HA) is a ubiquitous extracellular matrix (ECM) glycosaminoglycan synthesized by three
different enzymes, hyaluronan synthase (HAS)1, 2, and 3. HA synthesis mediated by HAS3 promotes inflammation
and is pathogenic in animal models of human lung and intestinal disease. Liver fibrosis is a common endpoint to
chronic liver injury and inflammation for which there is no cure. Although plasma HA is a commonly used biomarker
for liver disease, if and how HA contributes to disease pathogenesis remains unclear. Here, we tested the hypothesis
that HA synthesized by HAS3 enhances inflammation and fibrosis. To test this hypothesis, we exposed wild-type or
Has3−/− mice to carbon tetrachloride (CCl4) once (acute) or ten (chronic) times.
Results: HAS3-deficient mice exhibited increased hepatic injury and inflammatory chemokine production 48 h after
acute CCl4; this was associated with a threefold reduction in plasma HA levels and alterations in the proportions of
specific molecular weight HA polymer pools. Hepatic accumulation of fibrosis-associated transcripts was also
greater in livers from HAS3-deficient mice compared to controls after acute CCl4 exposure. Surprisingly, fibrosis
was not different between genotypes. Hepatic matrix metalloproteinase (MMP)13 mRNA and MMP13 activity
was greater in livers from Has3-null mice after chronic CCl4; this was prevented by a MMP13-specific inhibitor.
Collectively, these data suggest that Has3, or more likely HA produced by HAS3, limits hepatic inflammation
after acute injury and attenuates MMP13-mediated matrix metabolism after chronic injury.
Conclusions: These data suggest that HA should be investigated further as a novel therapeutic target for acute
and chronic liver disease.
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Background
Liver fibrosis is the end result of chronic hepatic injury
and inflammation coupled with incomplete tissue repair.
The net effect of incomplete repair over several cycles of
tissue injury is accumulation of extracellular matrix
(ECM) proteins. When prolonged, excessive ECM accu-
mulation impacts hepatic architecture and function. Sev-
eral agents cause liver fibrosis including alcohol, obesity,
viruses, congenital disorders, cholestasis, parasites, drugs,
and toxins [1, 2]. Regardless of etiologic agent, the pro-
gression to liver fibrosis occurs in only a subset of patients
and is affected by a host of additional factors including
genetics, environment, behavior, and various comorbidi-
ties [3]. While removal of the etiologic agent can attenuate
disease progression and even lead to fibrosis reversal in
some patients, no pharmacologic strategy yet exists to
“cure” advanced liver disease [4, 5]. Liver transplantation
is the only therapeutic option for advanced liver disease
not responsive to etiologic agent removal.
Hyaluronan (HA) is a non-sulfated, anionic glycosamino-
glycan which consists of repeating N-acetylglucosamine
and glucuronic acid disaccharide units [6]. Three HA
synthases exist in mammals: (HAS)1, 2, and 3 [7]. They
differ based on biosynthetic capacity, length of the HA
polymer synthesized, induction profiles, and tissue expres-
sion levels [7–9]. Generally speaking, HA is synthesized as
a high molecular weight (HMW) polymer by many cell
types including fibroblasts and vascular endothelial cells
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[10, 11]. When tissues are injured, HA is synthesized and
degraded and participates in the wound healing response
[11]. HMW-HA (250–2000 kDa) is a major component of
healthy articular joints, the vitreous humor of the eye, and
the skin and when synthesized in these injured tissues,
dampens inflammation [12]. HA is degraded by hyaluroni-
dases and reactive oxygen species under normal circum-
stances and also when tissues are injured into a polydisperse
population containing low molecular weight (LMW) frag-
ments (<250 kDa) which exacerbate inflammation [12].
Persistence of LMW-HA in chronically wounded tissue
contributes to disease pathogenesis in animal models of idio-
pathic pulmonary fibrosis [13]. Of the hyaluronan synthases,
HAS3 makes the smallest HA polymers ranging from 100
to 1000 kDa, which includes polymers in the LMW range
[8]. Consistently, published studies using animal models of
human lung and intestine disease show that HA synthesized
by HAS3 contributes to inflammation [14–16].
HA is used as a biomarker for liver disease severity; the
more advanced the liver disease, the greater the amount of
HA is found in the blood [17, 18]. This is likely due to a
combination of increased HA synthesis by hepatic stellate
cells and other cells [19, 20], as well as a reduced capacity
for HA uptake by dysfunctional liver sinusoidal endothelial
cells found in diseased liver [21]. Despite the relationship
between plasma HA levels and liver disease and the pro-
inflammatory role HA plays in other diseases, no studies
have determined whether or not HA has a direct role in
liver disease pathogenesis. In this study, we tested the hy-
pothesis that HAS3, or HA produced by HAS3, contributes
to liver inflammation and fibrosis by increasing the pro-
portion of LMW-HA polymers relative to HMW-HA
polymers. To test this hypothesis, we utilized the well-
characterized carbon tetrachloride (CCl4)-induced liver
injury and fibrosis model in wild-type mice and mice defi-
cient in HAS3 [22]. Due to a lack of HA synthesized by
HAS3, we predicted Has3−/− mice would exhibit reduced
inflammation and fibrosis after CCl4 exposure, similar to
the previously published studies [14–16]. Here, we provide
evidence that HAS3 plays divergent roles depending upon
whether liver injury is acute or chronic.
Results
Hepatic Has gene transcript accumulation and plasma HA
levels in wild-type and Has3−/− mice
Real-time polymerase chain reaction (PCR) was used to de-
termine the relative amounts of Has1, 2, and 3 in the livers
from wild-type and Has3−/− mice, at baseline. The accu-
mulation of Has1 transcripts was not different between ge-
notypes (Fig. 1a). Has3 transcripts were most abundant in
the livers from the wild-type mice and were approximately
fivefold more than Has1 transcripts. Has2 transcripts were
least abundant in both genotypes, between 1 and 5 % of
total Has1 levels. However, Has2, was 40 % greater in livers
from Has3−/− mice relative to wild-type mice suggesting
this enzyme may compensate, at least in part, for HAS3
deficiency at baseline.
Real-time PCR was again used to evaluate hepatic Has
gene transcript levels after acute CCl4 exposure. In wild-
type mice, Has1 levels were increased 20-fold above base-
line 24 h after CCl4 exposure and declined thereafter
Fig. 1 Hepatic Has enzymes and plasma HA levels in wild-type and
Has3−/− mice. a Real-time PCR was used to measure basal levels of
hepatic Has enzyme transcript accumulation in the wild-type and
Has3−/− mice. Data were normalized to 18S and then expressed as
fold change over wild-type hepatic Has1 content. Bars with different
alphabetical superscripts are significantly different from one another
(P < 0.05). b–d The mice were exposed to CCl4 and euthanized 24,
48, 72, or 96 h later. Control animals received an olive oil (oil) injection.
Real-time PCR was used to measure hepatic Has1 (b), Has2 (c), and
Has3 (d) in the livers from the wild-type and HAS3-deficient mice.
*P < 0.05 when compared to the wild-type mice at the same time
point. An ELISA-like assay (see the “Methods” section for details on this
antibody-independent assay) was used to determine HA concentration
in pooled plasma from the wild-type and Has3−/− mice either before
(e) or after (f) HA fractionation using molecular weight cut-off columns.
In e and f, the open symbols indicate wild-type mice while the closed
symbols indicate Has3−/− mice. Circles indicate HA pools less than
100 kDa, squares indicate HA pools between 100 and 300 kDa, and
triangles indicate HA pools greater than 300 kDa. Statistical analysis was
not performed on these pooled samples. See Table 1 for additional
details. n/a not applicable. N = 6–8 mice per experimental group
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(Fig. 1b). In the Has3−/− mice, hepatic Has1 transcripts
also increased 24 h after CCl4 exposure, but this level was
not different from that found in the wild-type mice (Fig. 1b).
Has1 transcripts were greater in the livers from the Has3
−/− mice relative to the wild-type mice 72 h after CCl4 ex-
posure. Has2 transcripts peaked in the wild-type mice
48 h after CCl4 exposure, but only 1.8-fold above baseline
(Fig. 1c). Unlike Has2 transcripts in the wild-type mice,
Has2 transcripts were not induced in the Has3−/− mice
until 48 h after CCl4 exposure (Fig. 1c). At this time point,
Has2 transcripts increased fivefold in the Has3−/− mice, but
this increase was not significantly different than that found
in the wild-type mice (P= 0.05, Fig. 1c). However, Has2 tran-
scripts were greater in the Has3−/− mice compared to the
wild-type mice 72 h after CCl4 exposure (Fig. 1c). Finally,
Has3 transcripts were induced approximately 20-fold over
baseline 24 and 48 h after CCl4 exposure in wild-type mice
and returned to baseline 72 h after CCl4 and increased
again 96 h after CCl4 (Fig. 1d). Taken together, acute CCl4
exposure induced all three Has transcripts in the liver;
Has1 and Has3 were most robustly induced.
Using an enzyme-linked immunosorbent assay (ELISA)-
like assay, we measured plasma HA levels in the wild-type
and Has3−/− mice. The Has3−/− mice had reduced
plasma HA levels when compared to the wild-type mice at
baseline, 24 h, and 48 h after CCl4 exposure (Fig. 1e). HA
levels were similar between genotypes at 72 h but greater
in the Has3−/− mice 96 h after CCl4 exposure (Fig. 1e).
These data suggested that other HAS enzymes did not
completely compensate for reduced HA biosynthetic
capacity found in the Has3−/− mice. Next, using specific
molecular weight cut-off columns to fractionate plasma
HA into three groups (<100 kDa, 100–300 kDa, and
>300 kDa), we found that the wild-type mice had more
HA in the 100–300 kDa molecular weight range, com-
pared to the Has3−/− mice, while the absolute amounts of
HA in the other fractions did not exhibit such large
differences between genotypes (Fig. 1f). The majority of
plasma HA was found in the 100–300 kDa fraction in
the wild-type and Has3−/− mice (Fig. 1f and Table 1).
However, relative to wild-type mice, the Has3−/− mice
exhibited an increased percentage of the <100 kDa HA
fraction, decreased percentage of the 100–300 kDa frac-
tion, and increased percentage of the >300 kDa HA
fraction at almost every time point after CCl4 exposure
(Table 1). These data suggested that, in addition to a reduc-
tion in total HA level, HA molecular mass distribution was
also perturbed in the Has3−/− mice, favoring lower mo-
lecular weight populations, relative to the wild-type mice.
Liver injury and steatosis after acute CCl4 exposure
The wild-type and Has3−/− mice were exposed to CCl4
and euthanized 24, 48, 72, and 96 h later. CCl4 induced
liver injury in both strains of mice, but this injury was
greater in the livers from the Has3−/− mice. Specifically,
peak plasma alanine aminotransferase (ALT) activity, a
measure of liver injury, was 41 % greater in the Has3−/−
mice relative to the control mice 48 h after CCl4 exposure
(Fig. 2a). Although plasma ALT activity was reduced 72 h
after CCl4 in both strains, it remained greater in the Has3
−/− mice (Fig. 2a). In support of these data, histopatho-
logical assessment revealed more necrosis in the livers from
the Has3−/−mice compared to the wild-type mice (Fig. 2b).
Hepatic triglyceride accumulation increased 24 h after CCl4
but was 31 % greater in the HAS3-deficient mice compared
to the controls (Fig. 2c). Liver histology paralleled these two
biochemical measures of the liver’s response to CCl4 in the
wild-type and Has3−/−mice (Fig. 2d). Increased macrovesi-
cular steatosis was more abundant in the livers from the
Has3−/− mice compared to the wild-type mice 24 h after
CCl4. Consistent with increased plasma ALT values, hepatic
architecture was more severely disrupted in the Has3−/−
mice 48 h after CCl4 exposure. Fewer hepatocyte nuclei
and more hemorrhage were present in the necrotic areas of
Table 1 Total and fractionated plasma HA content in wild-type and Has3−/− mice after acute carbon tetrachloride exposure
Group <100 kDa (ng/mL) % of total 100–300 kDa (ng/mL) % of total >300 kDa (ng/mL) % of total Total (ng/mL)
Wild-type mice
Oil 10 3 247 77 64 20 322
24 h 78 6 917 76 215 18 1210
48 h 109 7 1041 68 376 25 1526
72 h 38 7 330 58 199 35 567
96 h 7 3 135 65 66 32 208
Has3−/− mice
Oil 6 5 82 71 27 23 115
24 h 34 3 428 75 112 20 574
48 h 48 9 285 54 199 37 532
72 h 26 7 271 67 106 26 403
96 h 26 6 223 50 196 44 445
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the Has3−/− mice compared to the wild-type mice.
Seventy-two hours after CCl4, robust cellular infiltration
was found in the pericentral areas of the wild-type mice;
this infiltration was reduced in the livers from the Has3−/−
mice and was associated with more eosinophilic staining in
the pericentral areas (Fig. 2d). Ninety-six hours after CCl4
exposure, liver histology was largely back to normal and
not different between genotypes (data not shown).
CCl4 must be bioactivated to reactive metabolites
to induce hepatotoxicity [23]. To ensure that increased
liver injury in Has3−/− mice was not due to differences in
CCl4 bioactivation, we measured cytochrome P450 2E1
(CYP2E1) protein (Fig. 3a, b) and activity (Fig. 3c) levels;
there was no difference in these parameters between geno-
types. Surprisingly, in contrast to the pathogenic role HAS3
plays in injury in other animal models of human disease,
our data suggest that HAS3 plays a protective role in the
liver after acute CCl4 exposure.
Hepatic inflammation after acute CCl4 exposure in wild-type
and Has3−/− mice
We next investigated the impact HAS3-deficiency on hep-
atic inflammation. While inflammatory markers increased
in the livers from both strains of mice after CCl4 exposure,
these markers tended to be greater in the Has3−/− mice
compared to the wild-type mice. Specifically, using real-
time PCR, we found hepatic Ccl2, Cxcl1, and Cxcl10 were
increased in the Has3−/− mice (Fig. 4a–c). None of these
transcripts were different between genotypes at other time
points (data not shown). Consistently, using a cytokine
protein array, we found that plasma CCL2, CXCL1, and
CXCL10 chemokine proteins were also increased in the
Has3−/− mice (Fig. 4d–f ). High Cd11b expression is
associated with pro-inflammatory, infiltrating macro-
phages after acute liver injury [24]. While precise evalu-
ation of the inflammatory infiltrate is outside the goal of
this manuscript, we were able to detect an increase in
hepatic accumulation of Cd11b transcripts in Has3-/-
mice which approached significance (Additional file 1).
Effect of Has3-deficiency on hepatic stellate cell activation
and fibrosis after acute and chronic CCl4
Although acute CCl4 exposure does not cause fibrosis, it
does induce activation of hepatic stellate cells (HSC),
cells integral to hepatic wound healing through, in part,

























Fig. 2 Liver injury and steatosis in wild-type and Has3−/− mice. The mice were exposed to CCl4 and euthanized 24, 48, 72, or 96 h later. Control
animals received an olive oil (oil) injection. a Plasma ALT activity was determined using an enzymatic assay. b Histopathologic assessment of the
percent necrosis at baseline and 48 h after CCl4 exposure. c Total hepatic triglycerides were measured using a biochemical assay. d Representative
histology in the wild-type and Has3−/− mice (200×). Asterisks denote central veins, and plus signs denote the portal vein of the portal triad. The
necrotic areas are outlined with yellow dashed line in the 48 and 72 h images, and the area of macrovesicular steatosis is identified by black arrows
in the 24 h images. In every figure of this manuscript, white bars indicate wild-type mice while black bars indicate Has3−/− mice. *P < 0.05 compared
between genotypes at the same time point. N = 4–7 mice per experimental group
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injury and inflammation were increased in the Has3−/−
mice after acute CCl4 exposure, we predicted that the
wound healing response would also be increased. After
acute CCl4 exposure, markers associated with HSC activa-
tion were increased in both mouse strains. However, these
markers were greater in the livers from the Has3−/− mice
48 h after CCl4. Specifically, using real-time PCR, we
found that hepatic pro-fibrotic growth factor transcript
accumulation (transforming growth factor (Tgf ) β1 and
connective tissue growth factor (Ctgf )) were increased in
the livers from the Has3−/− mice (Fig. 5a, b). Consistent
with a role for these mediators in HSC activation, hepatic
α smooth muscle actin (αSMA, Acta2), type I collagen
(Col1a1, Col1a2), and heat shock protein 47 (Serpinh1),
the collagen-specific chaperone, were increased 48 h after
CCl4 exposure. These transcripts were each increased fur-
ther in the HAS3-deficient mice (Fig. 5c–f ). Collectively,
these data suggest that increased injury and inflammation
in the Has3−/− mice induces a more robust wound heal-
ing response in the liver after acute CCl4.
To evaluate the impact HAS3-deficiency had on frank
fibrosis, we administered CCl4 twice per week for 5 weeks
to wild-type and Has3−/− mice. Real-time PCR data re-
vealed no difference in actin alpha 2, smooth muscle, aorta
(Acta2) (αSMA) transcripts after chronic CCl4 exposure
(Fig. 6a). Col1a1 and Col1a2 transcript accumulation was
also induced in both strains and was increased in the
Has3−/− mice (Fig. 6b, c). Interestingly, and in contrast to
HA levels after acute CCl4, HA levels were not reduced in
the Has3−/− mice at baseline or 72 h after CCl4. Although
not significant, a trend to an increase in plasma HA was
observed in the Has3−/− mice after chronic CCl4 expos-
ure (Fig. 6d). Has enzyme transcript levels did not account
for this difference in plasma HA concentration (Fig. 6e).
To evaluate actual hepatic content of ECM proteins, liver
sections from each mouse were stained using Sirius red.
Semi-quantification of Sirius red staining demonstrated
established fibrosis in both strains of mice (Fig. 7a). How-
ever, after morphometry to quantify Sirius red-positive
staining, there was no difference in ECM accumulation
between genotypes (Fig. 7b). Consistently, collagen con-
tent, measured biochemically, was not different between
the wild-type and Has3−/− mice (Fig. 7c).
Evaluation of matrix remodeling in wild-type
and Has3−/− mice
Faced with an apparent paradox (i.e., increased liver injury,
inflammation, and fibrotic transcript accumulation after
acute liver injury but equivalent hepatic ECM content after
chronic liver injury), we hypothesized that the Has3−/−
mice had an increased ability to remodel their hepatic
ECM after chronic CCl4 exposure; increased ability to de-
grade the ECM could be responsible for the equivalent
ECM content in livers from both mouse strains. Using
real-time PCR, we evaluated hepatic accumulation of
matrix metalloproteinase (Mmp) and tissue inhibitor of
matrix metalloproteinase (Timp) transcripts after chronic
CCl4. While there was no difference in Mmp2, Mmp9, or
Timp1 (Fig. 8a–c), Mmp13 transcripts were increased in
the livers from the Has3−/− mice; there was no difference
between baseline Mmp13 transcript levels between ge-
notypes (Fig. 8d). We used immunoblotting to further
evaluate hepatic MMP13. We found that, under basal
conditions, the livers from the Has3−/− and wild-type
mice had a substantial active form of the MMP13 en-
zyme; the ratio between active and pro MMP13 was not
different between genotypes (Fig. 8e, f ). This likely reflects
normal matrix remodeling. However, after chronic CCl4
exposure, only the Has3−/− mice had an increase in the
ratio of active MMP13 to pro MMP13. To determine if
these changes in hepatic MMP13 resulted in increased
matrix remodeling, we performed in situ zymography, in
vitro, using dye-quenched gelatin as a substrate [25]. In
this technique, location, area, and intensity of a matrix-
degrading activity is visualized by the presence of green
fluorescence. This technique revealed matrix metabolism
in the fibrotic septae in the liver sections from the wild-
type and HAS3-deficient mice (Fig. 9a). However, the
intensity and total area of fluorescence (i.e., matrix re-
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b c
Fig. 3 CYP2E1 content and activity in wild-type and Has3−/− mice.
a Representative CYP2E1 immunoblot using samples from olive
oil-treated wild-type and Has3−/− mice. GAPDH was used as a loading
control. b Semi-quantification of hepatic CYP2E1 content after
normalization to GAPDH. Data are expressed as fold change over
wild-type mice (n = 6 each genotype). c Hepatic CYP2E1 activity
assay in microsomes isolated from the wild-type and Has3−/− mice
at baseline (before CCl4 exposure) (n = 6 mice per experimental group).
The data are expressed as fold change over wild-type. Pos cntl,
microsomes prepared from a single mouse fed an ethanol-containing
diet for 5 weeks (ethanol is known to increase CYP2E1). Neg cntl,
microsomes prepared from a single mouse exposed to CCl4 and
euthanized 24 h later (CCl4 consumptively depletes CYP2E1)
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(Fig. 9b, c). Importantly, when incubated with a MMP13-
specific inhibitor, matrix remodeling was reduced in the
livers from the Has3−/− mice; the inhibitor did not sup-
press matrix metabolism in the livers from the wild-type
mice. Therefore, even though the Has3−/− mice exhibited
worse liver injury, inflammation and pro-fibrotic gene
expression after acute CCl4, this did not precipitate in-
creased fibrosis after chronic CCl4 exposure. Instead,
the Has3−/− mice exhibited an increased capacity to
remodel the hepatic ECM during fibrosis limiting fi-
brotic disease.
Discussion
In this manuscript, we provide the first evidence to sug-
gest that HAS3, and presumably HA produced by HAS3,
plays differential roles after acute and chronic liver injury.
Specifically, HAS3 protects the liver after acute liver injury
by dampening hepatic inflammation. Our data suggest
that this protective effect may be due to the total amount
and relative proportions of critical molecular weight HA
pools. In addition, the HAS-deficient mice exhibited an
enhanced ability to remodel the ECM after chronic CCl4,
and this was dependent on MMP13. The presence of
more, lower molecular weight HA fragments in Has3−/−
mice may have driven the enhanced MMP13 response as
shown previously [26]. Enhanced matrix remodeling pre-
vented the increase in fibrosis we predicted based on hep-
atic fibrotic gene transcript accumulation in Has3−/−
mice after acute and chronic CCl4 exposure. Therefore,
HAS3-mediated HA production is pathologic in chronic
liver injury. This dichotomous relationship between the
roles for HAS3 after acute or chronic liver injury likely re-
flects important differences between where in the liver
wound healing continuum one looks.
Despite a well-appreciated role for plasma HA as a
hepatic function biomarker [18, 27, 28], few studies have
explored the role HA plays in pathogenesis or resolution
of liver disease. It is known that HSC can synthesize HA
and do so in response to partial hepatectomy, a surgical
model of liver regeneration [29]. In addition, treating
mice with HMW-HA (780, 900, or 1200 kDa), but not
LMW-HA (250 and 470 kDa), can prevent T cell mediated
liver injury (concanavalin A and galactosamine/lipopoly-
saccharide models), and this occurs through a reduction
in pro-inflammatory cytokines, including tumor necrosis
factor α, interferon gamma, macrophage inflammatory
protein 2 (MIP2), and interleukin 4 [30]. Administra-
tion of human umbilical vein HA (HMW-HA) also ex-
erts some protection against CCl4-induced liver injury,
lipid peroxidation, and fibrosis in rats when used in
combination with chondroitin sulfate, but not when ei-
ther molecule was used alone [31]. Collectively, these
studies, as well as our study, suggest that HA can ex-
hibit a protective effect in animal models of acute liver
disease.
While no one has yet explored the effect of HAS en-
zyme deficiency in animal models of liver injury, investiga-
tors have evaluated the impact HAS3 deficiency has in
other animal models of human disease; these studies
largely support a pathogenic role for HAS3. For example,
Fig. 4 Hepatic and plasma chemokine content in wild-type and Has3−/− mice. Forty-eight hours after CCl4 exposure, the mice were euthanized
and the livers were collected to determine the relative amounts of a Ccl2, b Cxcl1, and c Cxcl10 transcripts in both genotypes. Here and throughout
the manuscript, data were calculated using the 2−ΔΔCt method after normalization to 18S and are expressed as fold change over each genotype’s own
baseline (oil). Plasma isolated from blood collected at the same time points was used to determine the relative amounts of CCL2 (d), CXCL1 (e), and
CXCL10 (f) peptides using a protein array. For this assay, plasma samples were pooled per experimental group (n = 6–8 mice). The bar graphs in d–f
were created after semi-quantification of chemokine spot density from the array after densitometric analysis (spots not shown). *P < 0.05 compared
between genotypes at the same time point
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in the lung, Bai et al. demonstrated that high tidal volume,
ventilator-induced pulmonary MIP2 production, and neu-
trophil infiltration are robust in wild-type mice, but
suppressed in mice deficient in HAS3 [14]. The increase
in inflammation in wild-type mice is associated with in-
creased pulmonary accumulation of HA favoring lower
molecular weight species (178–370 kDa); this was not ob-
served in Has3−/− mice. Likewise, Kessler et al. demon-
strated that HAS3-null mice are protected from dextran
sodium sulfate (DSS)-induced colitis when compared to
wild-type mice [16]. In the absence of HAS3, HA de-
position and leukocyte infiltration are profoundly at-
tenuated and associated with reduced weight loss and
pro-inflammatory cytokine production after DSS expos-
ure. In both of these studies, and in contrast to our study,
HAS3 drives tissue inflammation.
The specific mechanisms behind pathogenic function
of HAS3 in the lung and in the gut remain controver-
sial. One hypothesis is that because HAS3 can make
smaller HA polymers compared to HAS1 and HAS2
[8], perhaps HAS3-synthesized HA is small enough to
Fig. 6 Hepatic fibrotic marker transcript accumulation and plasma
HA levels after chronic CCl4 exposure. The mice were exposed to
CCl4 for 5 weeks, twice per week, and were euthanized 72 h after
the final CCl4 exposure. Control animals received olive oil (oil) injections.
Hepatic a Acta2, b Col1a1, and c Col1a2 transcript accumulation was
determined using real-time PCR. The data are expressed as fold change
over each strain’s olive oil-treated control after normalization to
18S. d HA concentration was determined using an HA ELISA-like
assay (see the “Methods” section for details). e Hepatic Has enzyme
transcript levels in wild-type and Has3−/−mice. Data were normalized to
Has1 levels in wild-type mice at baseline. N= 5–6 mice per experimental
group. nd not detected, i.e., transcripts were below the level of detection,
n/a not applicable. *P< 0.05 compared between genotypes
Fig. 5 Hepatic fibrotic marker transcript accumulation after acute
CCl4 exposure. The mice were exposed to CCl4 and euthanized 48 h
later. Control animals received an olive oil (oil) injection. Hepatic a. Tgfβ1,
b Ctgf, c Acta2, d Col1a1, e Col1a2, and f Serpinh1 were measured using
real-time PCR. The data are expressed as fold change over each strain’s
olive oil-treated control after normalizing for input cDNA using 18S
(n = 6–8 mice per experimental group). *P < 0.05 compared between
genotypes at the same time point
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be pro-inflammatory on its own. Conversely, perhaps
LMW-HA synthesized by HAS3 is not directly pro-
inflammatory but because it is smaller initially, it is
more rapidly degraded into HA species which are pro-
inflammatory. Another possible explanation is that HAS
enzymes are differentially expressed in various tissues, cell
types, or in response to different stimuli. Therefore, loss
of one enzyme could profoundly influence the nature of
the inflammatory response to injury in a tissue or cell-
type-specific fashion [7]. Therefore HAS3’s differential
effect, pathologic vs protective depending on the animal







Fig. 7 Liver fibrosis in wild-type and Has3−/− mice after chronic CCl4 exposure. The mice were exposed to CCl4 for 5 weeks, twice per week, and
were euthanized 72 h after the final CCl4 exposure. Control animals received olive oil (oil) injections. a Sirius red was used to localize extracellular
matrix accumulation in the livers from the control and CCl4-treated mice (red bands around vascular units and extending from and connecting
neighboring central veins, ×100 magnification). b Semi-quantification of Sirius red staining expressed as a percent of total tissue area. Similar
quantification of Sirius red staining intensity was also performed, and no differences were observed between groups (data not shown). c Hepatic
hydroxyproline concentration was determined using a biochemical assay from which approximate collagen content was calculated (see the
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Fig. 8 Hepatic Mmp and Timp content in the livers from wild-type and Has3−/− mice. The mice were exposed to CCl4 for 5 weeks, twice per
week, then were euthanized 72 h after the final CCl4 exposure. Control animals received olive oil (oil) injections. Hepatic a Mmp2, b Mmp9,
c Timp1 and d Mmp13 transcript accumulation was evaluated using real-time PCR. Data are expressed as fold change over each strain’s baseline
(oil) after normalization to 18S. e Representative immunoblot of hepatic pro and active MMP13 protein. GAPDH is used to demonstrate equal
loading. f Semi-quantification MMP13 band densities expressed as relative amount of active MMP13 relative to pro MMP13. N = 5–6 mice per
experimental group. *P < 0.05 compared between genotypes
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explored further by evaluating in which cell types
HAS3 is expressed as well as by elucidating the local
production and turnover of HA after tissue injury. In-
deed, in the DSS-induced colitis model, HAS3 expres-
sion is predominantly localized to the endothelial cells
found in gut microvessels where it produces a leukocyte-
adhesive HA and contributes to inflammation [32]. Fur-
ther exploration of cell-type-specific hepatic HAS enzyme
expression, hepatic HA accumulation, and hepatic HA
molecular weight distribution during liver disease patho-
genesis, progression, or resolution is required to under-
stand the differences between our study and the other
studies discussed above.
In this study, we observed increases in hepatic mRNA
and plasma protein levels for chemokines and CD11b, a
marker associated with monocyte recruitment to the liver
[24] associated with tissue inflammation. These chemokines
can attract a number of cells involved in innate an adaptive
immune responses to tissue injury including monocytes/
macrophages (CCL2, CXCL10), neutrophils (CXCL1), nat-
ural killer cells (CXCL10), dendritic cells (CCL2, CXCL12),
and T cells (CCL2, CXCL10). We believe that chemokine
production is at a critical nexus between the promotion of
liver injury and, paradoxically, resolution of fibrosis. Indeed,
while CYP2E1-mediated bioactivation is required for CCl4’s
hepatotoxic effects [33], macrophages and macrophage re-
cruitment also contribute to liver injury in this model.
Specifically, if macrophages are depleted using gadolin-
ium chloride, liver injury after CCl4 exposure is re-
duced [34]. Similarly, the mice deficient in CCL2 or the











Fig. 9 Matrix metabolism in wild-type and Has3−/− mice after chronic CCl4 exposure. Mice were exposed to CCl4 for 5 weeks, twice per week,
then were euthanized 72 h after the final CCl4 exposure. Control animals received olive oil (oil) injections. a In situ zymography in the wild-type
and Has3−/− mice. In the first column under each genotype, green fluorescence (Oregon Green 488) reveals matrix-degrading activity. In the
second column, images were captured after DAPI staining to visualize hepatic nuclei. The third column contains merged images (green fluorescence
and DAPI). a MMP13-specific inhibitor (Inh) was used to attenuate MMP13-specific matrix-degrading activity; EDTA was used to block all MMP activity.
b Intensity of green fluorescence and c area of green fluorescence above threshold were determined using ImageJ. N = 5–6 mice per experimental
group. *P < 0.05 compared between genotypes; **P < 0.05 when compared to untreated (no Mmp13 inhibitor) and to wild-type treated with
MMP13 inhibitor
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CCL2 receptor, CCR2, exhibit reduced plasma ALT ac-
tivities, intrahepatic inflammatory cytokine expression,
and macrophage recruitment after CCl4 exposure [35, 36].
Therefore, increased inflammatory macrophage recruit-
ment in response to increased chemokine production in
Has3−/− mice could contribute to increased injury after
CCl4 exposure.
In addition to exacerbating liver injury and inflamma-
tion, hepatic macrophages and macrophage recruitment
are also critical determinants of fibrosis resolution. For
example, depleting macrophages with diphtheria toxin
using a CD11b-diphtheria toxin receptor transgenic mouse
attenuates matrix degradation in fibrotic liver [37]. Like-
wise, CCl4-induced fibrosis resolution is reduced when
macrophage recruitment is prevented in CCR2-deficient
mice [36]. Therefore, enhanced chemokine production in
response to acute CCl4 could facilitate better fibrosis reso-
lution by recruiting more macrophages to the injured liver.
As described by others, MMP13 is critical for resolution
of liver fibrosis in mice and is associated with a resolution-
associated macrophage population called scar-associated
macrophages (SAMs) [38]. MMP13 degrades fibrillar
collagen and also exhibits gelatinase activity [39, 40]. Con-
sistently, in mice with reduced hepatic SAMs, fibrosis
resolution after cessation of CCl4 exposure is delayed and
associated with reduced hepatic expression of Mmp13
mRNA and active MMP13 enzyme [36, 41]. It is important
to note, however, that global deletion of MMP13 reduces
fibrosis after bile duct ligation (BDL). Uchinami et al. dem-
onstrated that reduced liver injury and inflammation in
MMP13-deficient mice was responsible for the diminished
fibrotic response after BDL [42]. This suggests that the role
MMP13 plays in different points in the wound healing re-
sponse may be critical to its overall impact on fibrosis. In
this study, we found increased Mmp13 transcript accumu-
lation, active form of MMP13 and MMP13 enzyme activity
after chronic CCl4; we believe this contributed to the in-
creased matrix remodeling in the Has3−/− mice. HA oli-
gosaccharides are known inducers of MMP13 [26] It is
tempting to speculate that increased HA levels found in
the Has3−/− mice after chronic exposure to CCl4 may
have contributed to the increase in MMP13 levels we
found in this study. While beyond the scope of this manu-
script, we are currently exploring macrophage phenotype
in Has3−/− mice after chronic CCl4 and the response of
macrophages to specific HA polymer sizes to more clearly
understand the mechanism behind the observations made
in this study.
Conclusions
We have demonstrated that HAS3, or HA synthesized
by HAS3, is a critical determinant of the divergent out-
comes observed after acute and chronic liver injury in
response to CCl4. Importantly, our data suggest that HA
plays two roles in the liver, one in which it attenuates
liver injury and inflammation and one in which it exac-
erbates fibrosis. Further work is required to understand
this apparently dichotomous relationship between HA
and acute vs chronic liver injury and leverage that infor-




Primary antibodies used include the following: CYP2E1
(Abcam, Cambridge, MA), MMP13 (clone LIPCO-IID1,
Abcam), and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Cell Signaling, Clone 14C10, Beverly, MA). A
horseradish peroxidase (HRP)-conjugated goat-anti-rabbit
secondary antibody (Abcam) was used for the primary anti-
bodies listed above. Olive oil and carbon tetrachloride were
purchased from Sigma-Aldrich (St. Louis, MO), Buprenex
analgesic (buprenorphine HCl) was manufactured by
Reckitt Benckiser Healthcare (UK, Ltd, Hull England)
and distributed by Reckitt Benckiser Pharmaceuticals, Inc.
(Richmond, VA). Anesthetics used were from the follow-
ing sources: ketamine (Akorn, Inc, Decator, IL), xylazine
(KetaVed, VedCO, Inc., St. Joseph, MO), and aceproma-
zine (VedCO, Inc.). Pyrimidine-4,6-dicarboxylic acid, bis-
(4-fluoro-3-methyl-benzylamide) was used as a selective
MMP13 inhibitor (EMD Millipore/Calbiochem, Billerica,
MA, catalog number #444283).
Animal care
The animals were treated humanely and in accordance to
protocols approved by the University of Kansas Medical
Center’s (KUMC) Institutional Animal Care and Use
Committee (IACUC). The mice were housed in ventilated
cages on a 10/14-h light/dark cycle with access to stand-
ard mouse chow and water ad libitum. The Has3−/− mice
were generated by Bai et al. through gene targeting, elim-
inating the catalytic site of the HAS3 enzyme [14]. Male
Has3−/− mice (C57BL/6J background, confirmed by NNT
genotyping) were bred at KUMC. Age-matched, wild-type
(C57BL/6 J), male mice (acute CCl4 studies, see below) or
female and male mice (chronic CCl4 studies) were pur-
chased from Jackson Labs (Bar Harbor, ME) and used
within 2 weeks of arrival at KUMC. There were no differ-
ences in disease pathogenesis parameters between male
and female mice in chronic CCl4 studies. NNT genotyping
confirmed that the Has3−/− mice and C57BL/6J mice
were on the same (BL/6J) genetic background.
Carbon tetrachloride exposure, tissue collection,
and storage
In acute CCl4 studies, the mice were given a single intra-
peritoneal (i.p.) injection of CCl4 at a concentration of
0.4 mg/g body weight diluted 1:3 in olive oil. In the chronic
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studies, the mice were given two CCl4 injections per week
for 5 weeks ramping up from 0.1 mg/g BW (one injection)
to 0.2 mg/g BW (one injection) to 0.4 mg/g BW (8 eight
injections). Subcutaneous administration of an analgesic
(buprenorphine) preceded each CCl4 injection by 10 min
as done previously [43] and on recommendation by the
KUMC IACUC. The control mice received analgesic and
olive oil injection(s). Twenty-four, 48, 72, or 96 h (acute) or
72 h (chronic) post CCl4, the mice were anesthetized using
a cocktail of ketamine (200 mg/kg), xylazine (40 mg/kg),
and acepromazine (20 mg/kg). Blood was collected from
the inferior vena cava into EDTA and aprotinin-containing
tubes and placed on ice. After the blood was collected, the
diaphragm, superior vena cava, and aorta were cut euthan-
izing the mouse. After euthanasia, a hepatectomy was per-
formed. The liver was divided into several pieces while on
an ice-chilled piece of glass: the small half of the median
lobe was cut into three pieces and placed into 2-mL tubes
with 1.5 mL of RNAlater (Life Technologies, Grand Island,
NY) stored at room temperature for 5 min, at 4 °C for 18 h
and then transferred to −20 °C until use. A portion of the
large half of the median lobe was embedded in Optimal
Cutting Temperature (OCT) medium, incubated on a bed
of frozen isopentane until the OCT was opaque and then
stored at −80 °C. The largest lobe of the liver (left lobe)
was cut into several slices, and some of which were used
for Western blot analysis (snap frozen in liquid nitrogen,
stored at −80 °C) or fixed in formalin and later embedded
in paraffin for histological analysis. The right lobe was snap
frozen in liquid nitrogen and then stored at −80 °C for tri-
glyceride quantification. All remaining liver tissue was snap
frozen and archived at −80 °C; CYP2E1 activity assays were
performed using pieces from the left lobe. The blood was
centrifuged at 10,000×g for 3.5 min. Plasma was separated
into two aliquots and frozen at −80 °C until use.
Liver injury and hepatic triglyceride content determination
Plasma alanine aminotransferase (ALT) activity was de-
termined using a commercially available enzymatic assay
(Sekisui Diagnostics, Exton, PA) according to the manu-
facturer’s instructions. Activity was calculated using the
extinction coefficient method. For triglyceride measure-
ment, the livers were digested with 3 M KOH in 65 %
ethanol for 1 h at 70 °C and vortexed every 20 min to aid
in tissue disruption. Twenty-four hours later, samples were
diluted 1:5 in 2 M tris pH 7.5, 10 μL was added to trigly-
ceride GPO reagent (Trinder method), and absorbances
were read at 500 nm. A standard curve created using a
GPO standard was used to calculate total hepatic triglycer-
ide content (Pointe Scientific, Canton, MI).
Histological analysis
Formalin-fixed, paraffin-embedded sections were cut (5 μM)
and stained with hematoxylin and eosin. Micrographs were
taken at ×200 magnification using an Olympus BX51 micro-
scope fitted with an Olympus DP71 camera (Olympus,
Waltham, MA). DP Controller software was used to ac-
quire images (Olympus, Waltham, MA). Three non-
overlapping images per liver section were acquired and
viewed by a blinded individual (MFO). Assessments were
made on a scale from 0 to 4+ for the following parame-
ters: cellular infiltrate, steatosis, necrosis, and hemorrhage.
Immunoblotting
Liver lysates were prepared as described [43], and samples
were resolved on 10 % SDS-PAGE gels. Proteins were
transferred to PVDF membranes, blocked in 5 % BSA, and
then probed for proteins of interest overnight at 4 °C with
agitation. HRP-conjugated secondary antibodies were used,
and after incubation in an Enhanced Chemiluminescent
substrate (GE Healthcare, Piscataway, NJ), luminescence
was captured using radiographic film. Quantification of
band density was achieved using ImageJ. Data were nor-
malized to a housekeeping gene (GAPDH).
CYP2E1 activity assay
Liver microsomes were prepared by homogenizing 100–
150 mg of frozen liver tissue in 1 mL of cold PBS with a
loose fitting dounce homogenizer. After centrifugation at
9000×g for 15 min, the fat layer was removed from the
surface of the liquid and 10 mL of cold PBS was added
and the homogenate was centrifuged at 105,000×g for 1 h
at 4 °C. The pellet was resuspended in 0.15 M KCl, and
the total protein concentration was determined by BCA
assay (Life Techologies/Pierce, Grand Island, NY). Four
microliters of 10 mM p-nitrophenol, and 10 μL phosphate
buffer (4 mL 1 M K2HPO4 + 1 mL 1 M KH2PO4 pH 7.4)
were added to 30 μg of protein; water was added to bring
the total volume to 100 μL. Ten microliters of freshly pre-
pared NADPH (10 nM) was then added, and the samples
were incubated at 37 °C in a water bath for 1 h. Following
incubation, 30 μL of 20 % trichloroacetic acid was added,
and the samples were vortexed, then centrifuged 10,000×g
for 10 min. One hundred microliters of supernatant was
added to 10 μL 10 N NaOH, and absorbance was deter-
mined at 510 nm. CYP2E1 activity was calculated using
the extinction coefficient of 9.53 × 105 M−1 cm−1, normal-
ized to protein concentration, and expressed as fold change
over wild-type, oil-exposed (control) mice.
RNA isolation, cDNA synthesis, and real-time PCR
RNAlater-stabilized liver pieces (20–30 mg) were homog-
enized (FastPrep 24, MP Biomedicals, Solon, OH) in RLT
buffer (RNeasy Mini Kit, Qiagen, Valencia, CA) with
10 μL of β-mercaptoethanol per mL of RLT. RNA was
then isolated using an RNeasy Mini Kit; 4 μg of RNA was
reverse transcribed into complementary DNA (cDNA)
using a Retroscript kit (Life Technologies/Ambion, Grand
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Island, NY). SYBR green (BioRad Universal Super Mix,)
was used for real-time PCR in a BioRad CFX384 real-time
PCR machine, and results were calculated using 2−ΔΔCt
method. Data were expressed as fold change over olive
oil-treated mice within a genotype. Primers utilized in this
study are found in Table 2; 18S was used as the house-
keeping gene and did not differ between genotypes or
time points after CCl4. Sequence sources are noted in the
table, most of which were obtained from the PrimerBank
(http://pga.mgh.harvard.edu/primerbank/) [44–46].
Cytokine protein array
Plasma cytokine protein content was measured using a
Proteome Profiler: Mouse Cytokine Array Panel A (R&D
Systems) to evaluate inflammatory mediators present in
pooled plasma samples from the mice exposed to CCl4 and
euthanized 48 h later or in animals exposed to olive oil
(control). In brief, pooled plasma samples (n= 6–8 individual
mice per group) were applied to the provided membrane
impregnated with capture antibodies. Streptavidin-HRP-
conjugated secondary antibodies were then applied, and
chemiluminescent technology was used to detect proteins
captured by the array. All arrays were done on the same day
with the same exposure time. NIH ImageJ was used to
semi-quantify pixel density of resultant cytokine-
positive areas recorded using radiographic film.
Size-selective HA fractionation and quantification
Quantikine ELISA for HA (R&D Systems, Minneapolis,
MN) was performed per manufacturer’s instructions to
determine the total HA content in plasma. Because HA
is a carbohydrate, the ELISA did not utilize capture and
detection antibodies. Instead, it utilized HA-binding pro-
teins (HABP). The wells of a 96-well plate were coated
with a capture HABP by the manufacturer. A biotinyl-
ated HABP was utilized as a detection reagent. We refer
to this modified ELISA as an “ELISA-like assay” in this
study. Determination of a size-specific HA fraction in
plasma was done as described previously [47], with modi-
fication. Briefly, plasma was pooled (n = 4–8 mice per time
point) and digested 1:1 with 10× Proteinase K solution at
60 °C for 4 h. Molecular weight cut-off columns (Centrisart,
100 and 300 kDa, Sartorius, Goettingen, Germany)
were used to isolate HA with molecular weights less
than 100 kDa, between 100 and 300 kDa and greater
than 300 kDa from the wild-type and Has3−/− mice.
Sirius red staining, image acquisition and data collection
Formalin-fixed, paraffin-embedded liver tissue sections
were incubated at 60 °C for 20 min, deparaffinized in
SafeClear (xylene substitute, protocol II), and rehydrated
in a graded series of ethanol. Slides were then immersed
in 0.1 % picrosirius red solution (Direct Red 80, in satu-
rated picric acid) for 1 h at room temperature. Acidified
water (0.5 % glacial acetic acid in water) was used to
wash the slides three times for 5 min each. The slides
were dehydrated in a reverse series of graded ethanol
and fresh SafeClear solutions, mounted using Permount
and glass coverslips and allowed to dry. An Olympus
BX51 microscope and Olympus DP71 camera were used to
Table 2 Primers used for real-time PCR transcript analysis
Gene name Protein Gen bank acc # Sequence source Forward primer Reverse primer
Has1 Has1 NM_008215 PrimerBank: 6680169a1 GGCGAGCACTCACGATCATC AGGAGTCCATAGCGATCTGAAG
Has2 Has2 NM_008216 Matrix Biol. 30(2):126–134, 2011 GGTCCAAGTGCCTTACTGAAAC TGTACAGCCACTCTCGGAAGTA
Has3 Has3 NM_008217 PrimerBank: 6680173a1 GTGGGCACCAGTCTGTTTG CCACTGAACGCGACCTCTG
Ccl2 CCL2/MCP1 NM_011333 Immunol. Cell Biol. 89:716, 2011 AGGTCCCTGTCATGCTTCTG TCTGGACCCATTCCTTCTTG
Cxcl1 CXCL1/GRO1/KC NM_008176 PrimerBank: 229577225c1 ACTGCACCCAAACCGAAGTC TGGGGACACCTTTTAGCATCTT
Cxcl10 CXCL10/IP10 NM_021274 PrimerBank: 10946576a1 CCAAGTGCTGCCGTCATTTTC GGCTCGCAGGGATGATTTCAA
Cd11b CD11b NM_001082960 PrimerBank: 132626288c3 GGGAGGACAAAAACTGCCTCA ACAACTAGGATCTTCGCAGCAT
Tgfb1 TGFβ1 NM_011577 PrimerBank: 6755774b1 AGCTGGTGAAACGGAAGCG GCGAGCCTTAGTTTGGACAGG
Ctgf CTGF NM_010217 PrimerBank: 6753878a1 GGGCCTCTTCTGCGATTTC ATCCAGGCAAGTGCATTGGTA
Acta2 αSMA NM_007392 PrimerBank: 31982518b1 CCCAGACATCAGGGAGTAATGG TCTATCGGATACTTCAGCGTCA
Col1a1 COL1A1 NM_007742 World J. Gastroenterol.
4(12):356, 2012
ATGTTCAGCTTTGTGGACCTC CAGAAAGCACAGCACTCGC
Col1a2 COL1A2 NM_007743 Am. J. Pathol. 176(6):2743, 2010 GGTGAGCCTGGTCAAACGG ACTGTGTCCTTTCACGCCTTT
Serpinh1 HSP47 NM_009825 PrimerBank: 6753304a1 GCCGAGGTGAAGAAACCCC CATCGCCTGATATAGGCTGAAG
Mmp2 MMP2 NM_008610 PrimerBank: 47271505b1 GATGTCGCCCCTAAAACAGAC CAGCCATAGAAAGTGTTCAGGT
Mmp9 MMP9 NM_013599 PrimerBank: 31560795b2 GGACCCGAAGCGGACATTG GAAGGGATACCCGTCTCCGT
Mmp13 MMP13 NM_008607 PrimerBank: 291463259b1 TGTTTGCAGAGCACTACTTGAA CAGTCACCTCTAAGCCAAAGAAA
Timp1 TIMP1 NM_011593 PrimerBank: 6755795a1 GCAACTCGGACCTGGTCATAA CGGCCCGTGATGAGAAACT
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acquire images at 100× magnification using DP Controller
software (Olympus, Waltham, MA). Five non-overlapping
images per liver section were acquired. One liver section
per mouse in each experimental group was photographed
(n = 5–6 mice per group). ImageJ was used to quantify the
area of positive staining above an arbitrary threshold which
remained constant for all images.
Hydroxyproline quantification and calculation of
collagen content
Collagen content was determined using the hydroxypro-
line assay as described by Reddy and Enwemeka [48].
Briefly, 10 mg of liver tissue was digested in water and
12.1 N HCl at 120 °C for 3 h using a dry bath incubator.
The samples were vortexed every 30 min during this in-
cubation period. The samples were centrifuged 10,000×g
for 10 min after the incubation was complete. Ten mi-
croliters of the resulting supernatant was placed, in du-
plicate, into wells of a 96-well plate. Hydroxyproline
standards (0–1 μg/well) were also added to the plate, in
duplicate. One hundred microliters of chloramine-T so-
lution was added to each well and incubated for 25 min
at room temperature, after which 100 μL of Ehrlich’s so-
lution was added to each well and incubated further for
35 min at 60 °C in a dry heat incubator. Absorbances
were measured at 550 nm, and the concentration of hy-
droxyproline was calculated from the standard curve.
Collagen content was estimated by dividing the hydroxy-
proline concentration by 12.5 %.
In situ zymography, image acquisition and data collection
Frozen tissue sections (7 μm) were taken from −80 °C and
immediately incubated with developing buffer (100 mM
Tris, pH 7.4, 100 mM NaCl, 5 mM CaCl2, 0.05 % Brij-35,
0.25 mM PMSF) containing 0.1 mg/mL Oregon green
488, dye-quenched (DQ) gelatin (Life Technologies/Mo-
lecular Probes, Grand Island, NY). To a second set of sec-
tions, an MMP13 inhibitor (EMD Millipore/Calbiochem,
Billerica, MA, catalog number #444283) was added. This
MMP13 inhibitor is also known as pyrimidine-4,6-di-
carboxylic acid, bis-(4-fluoro-3-methyl-benzylamide), a
non-zinc-chelating inhibitor of MMP13 [49]. It works by
binding to the catalytic domain of the enzyme, preventing
its activity. The slides were incubated in a humid chamber
at 37 °C for 16–18 h. After this incubation, 4′,6-diami-
dino-2-phenylindole (DAPI) mounting medium was used
as a nuclear counterstain and aqueous mounting medium,
and then sealed using clear nail polish. An Olympus BX51
microscope with an Olympus BH2RFLT3 burner, Olympus
DP71 camera, and DP Controller software were used to
capture three non-overlapping images from each tissue sec-
tion at 200× magnification. The exposure time was chosen
to minimize autofluorescence in control liver sections and
used for each subsequent image. ImageJ was used to
quantify area and intensity of the fluorescent signal gener-
ated by matrix metabolism.
Statistics
Data were collected from several independent experi-
ments. All results are presented as means ± SEM or indi-
vidual values alone. Statistical significance was defined as
P ≤ 0.05 and denoted with an asterisk (*). Student’s t test
was used when comparing two data sets, and ANOVA
was used when comparing more than two data sets and
included a Tukey’s adjustment for multiple compari-
sons. Analyses were performed using SAS (Cary, NC),
GraphPad Prism 6 (La Jolla, CA), or Excel (Microsoft,
Redmond, WA).
Additional file
Additional file 1: Hepatic Cd11b transcript analysis. Real-time PCR was
utilized to determine hepatic accumulation of Cd11b transcripts in
wild-type and Has3−/− mice at baseline (oil) or 48 h after CCl4 exposure.
(PDF 23 kb)
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